Eiger BioPharmaceuticals, Inc. (EIGR) News

Eiger BioPharmaceuticals, Inc. (EIGR): $7.40

1.80 (+32.14%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add EIGR to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#168 of 370

in industry

Filter EIGR News Items

EIGR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest EIGR News From Around the Web

Below are the latest news stories about EIGER BIOPHARMACEUTICALS INC that investors may wish to consider to help them evaluate EIGR as an investment opportunity.

Eiger BioPharmaceuticals Insiders US$2.1m Short Of Breakeven On Stock Purchase

Insiders who purchased US$3.42m worth of Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) shares over the past year...

Yahoo | December 4, 2023

Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today reported financial results for the third quarter 2023 and provided a business update.

Yahoo | November 9, 2023

Why Is Eiger BioPharmaceuticals (EIGR) Stock Down 31% Today?

Eiger BioPharmaceuticals (EIGR) stock is falling on Wednesday after the biopharmaceutical company halted a Phase 3 clinical trial.

William White on InvestorPlace | September 13, 2023

Why Is Sigma Lithium (SGML) Stock Up 14% Today?

Sigma Lithium (SGML) stock is climbing higher on Wednesday after confirming it has received multiple strategic proposals.

William White on InvestorPlace | September 13, 2023

WKHS Stock Alert: The $40,000 Reason Workhorse Is Up Today

Workhorse (WKHS) stock is on the rise Wednesday thanks to a new update from the IRS concerning its electric vehicle (EV) manufacturer status.

William White on InvestorPlace | September 13, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

It's time for another dive into the biggest pre-market stock movers as we check out all the shares worth watching on Wednesday!

William White on InvestorPlace | September 13, 2023

UPDATE 1-Eiger to discontinue hepatitis drug study over safety concerns

Eiger BioPharmaceuticals Inc said on Tuesday it would discontinue a late-stage study testing its experimental drug to treat the most severe form of viral hepatitis, due to safety concerns. The drug candidate, peginterferon lambda, was being tested in patients with chronic hepatitis delta (CHD). "The study discontinuation is disappointing, especially for patients with chronic hepatitis delta who have limited treatment options," said Eiger CEO David Apelian.

Yahoo | September 12, 2023

Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced its decision to discontinue the Phase 3 LIMT-2 study of peginterferon lambda in patients with chronic hepatitis delta (CHD). The decision is based on the recommendation of the Data Safety Monitoring Board (DSMB) for the study following its quarterly safety review. In a communication dated September 7, 2023, the

Yahoo | September 12, 2023

Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that David Apelian, MD, PhD, MBA, CEO of Eiger, will present a company overview at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023 at 7:00 AM ET in New York, NY. Eiger will also host one-on-one meetings with investors at the conference.

Yahoo | September 5, 2023

While dollars continue to flow into biotech, companies cut more jobs

Biotech continues to have a big impact on the local and state economy, a new report says. But mature clinical-stage companies also are struggling.

Yahoo | August 14, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!